Granules India Ltd
Granules India Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products. Oncology portfolio expected to start generating revenue from FY '28 onwards, with multiple filings planned quarterly.
From Granules India Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products.
- Expansion of the Europe and Rest of World (ROW) business, focusing on finished dosages and increasing API and PFI business.
- Increased focus on formulation segment, aiming for around 25% of revenues from API with emphasis on in-house consumption.
- Genome Valley formulation site to play a significant role in revenue growth, especially as Gagillapur facility normalizes post-remediation.
- Strategic shift towards high-margin finished dosage products leading to improved gross margins.
- Granules Life Sciences capacity utilization projected to increase from about 40% in current year to over 90% next year, driving revenue growth.
- Planned continuous R&D and new product launches to sustain medium to long-term growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Granules India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Granules India spent Rs. 313 crores on Granules Life Sciences (GLS) in FY '25, with additional CAPEX planned in FY '26.
- CAPEX for FY '26 is guided at Rs. 600 crores, covering GLS expansion, oncology, and peptide investments.
- CZRO project CAPEX is minimal in FY '25, focusing on land acquisition and pilot facilities; expansion to proceed cautiously.
- Peptide R&D facility is being set up in Hyderabad, followed by peptide manufacturing.
- Senn Chemicals acquisition involves ongoing CAPEX for enhancing CDMO capabilities and GLP-1 product development; the investment is over and above the Rs. 600 crore CAPEX for Granules.
- Total CAPEX including Senn Chemicals is expected to be around Rs. 1,100 crores (Rs. 600 crores + Rs. 450 crores enterprise value for Senn).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Granules India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Granules India has a strong and diverse product portfolio with a total of 127 dossiers filed across various regions.
- They have 85 ANDAs in the US (16 pending approval), 18 dossiers in Europe (10 pending approval), and 24 in other regions including Canada (8 pending approval).
- In Q4 FY '25, they filed 3 US ANDAs and 6 European dossiers, including a first-to-file product from the GPI facility.
- The oncology pipeline includes around 10 products under development with filings already initiated in US and Europe.
- The ADHD portfolio has about 10 products in the pipeline, including day 1 launches, day 181 opportunities, and some first-to-file.
2 more points management made on order book & pipeline
Granules India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.5K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Granules India Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Granules India Ltd Q4 FY25 results?
Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products. Oncology portfolio expected to start generating revenue from FY '28 onwards, with multiple filings planned quarterly.
What is Granules India Ltd share price analysis?
Granules India Ltd currently shows a neutral. The stock trades at a P/E of 32.2 with a market cap of ₹20,941 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India Ltd planning capital expenditure?
Granules India spent Rs.
Keep Granules India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.